Industry-Sponsored Research Week

Weill Cornell in collaboration with CareDx to develop test for rejection in kidney transplants


By David Schwartz
Published: May 12th, 2020

Weill Cornell Medicine has entered a commercialization partnership with precision medicine company CareDx, Inc. that gives the company exclusive development rights for UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.

CareDx struck the multi-year collaboration deal with Weill Cornell Medicine after studies showed the UroMap technology is able to distinguish acute rejection episodes with high accuracy, and may predict future development of an acute rejection episode.

The technology was developed by Dr. Manikkam Suthanthiran, a pioneer in molecular diagnostics and chief of nephrology, hypertension and transplantation medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.

CareDx plans to add UroMap to its suite of kidney transplant solutions, which includes AlloSure® and KidneyCare™, which they hope can provide healthcare professionals a comprehensive view of immune and injury status of the transplanted kidney. The company focuses on patient management and support tools that optimize immunosuppression.

“UroMap provides early detection and quantification of clinically relevant cellular rejection,” said Dr. Suthanthiran, who is also the named inventor on the patent for the urine gene expression technology. “We are hopeful that this test will benefit kidney transplant patients.”

“We are delighted to announce this collaboration with Weill Cornell Medicine to help bring UroMap’s rapid allograft rejection detection capabilities to our industry-leading suite of transplant care solutions,” said Peter Maag, CEO of CareDx. “We continue our commitment to fund research and drive innovation for transplant patient care.”

CareDx acquired rights to the UroMap technology through an exclusive license agreement with Cornell University, which was negotiated the school’s technology transfer office, the Center for Technology Licensing.

Source: Globe Newswire

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment